[1] |
TAI Jun, YU Miao, ZHANG Lin, LEI Yi, LIU Junting, LI Tao, HUANG Guimin, CHENG Yijing, NIE Xiaolu, WANG Qing.
Active monitoring of adverse reactions related to haemocoagulase agkistrodon for injection in children
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1011-1016.
|
[2] |
ZHAO Yan, LIU Wenbo, ZHAO Yifei, LI Dong, ZHENG Lijia, SONG Yana, ZHAO Yujuan, DONG Fang.
Applicability of patient registry research to regulation of medical devices
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(4): 423-427.
|
[3] |
ZHENG Yujing, ZHAO Zinan, JIN Pengfei, ZHAO Fei, HU Xin, ZHANG Yatong.
Active monitoring of adverse reactions of capecitabine-induced hand-foot syndrome based on the hospital information system
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(4): 441-443.
|
[4] |
ZHAO Yan, LI Yao, SONG Ya’na, ZHENG Lijia, LI Dong, ZHAO Yifei, BIAN Rongrong, DONG Fang.
Post-marketing active monitoring of medical devices under vigilance
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(12): 1385-1390.
|
[5] |
ZHENG Yi, ZHAI Yinghong, GUO Xiaojing, XU Jinfang, CHI Lijie, GUO Zhijian, CHEN Chenxin, LIANG Jizhou, WEI Lianhui, CHEN Xiao, YE Xiaofei, HE Jia.
Thyroid immune-related adverse reactions of immune checkpoint inhibitors
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(1): 92-95.
|
[6] |
XIONG Daiqin, MA Xueying, TENG Liang, WANG Jie.
An Active Model for Monitoring and Early Warning of Cephalosporin Adverse Drug Reactions in Pediatrics Using Global Trigger Tools
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(7): 663-668.
|
[7] |
WANG Dan, REN Jingtian, WU Guizhi, XIONG Weiyi, TANG Ren, PANG Yu, FAN Rong, YANG Le.
Significance of Good Pharmacovigilance Practice in the Construction of China Pharmacovigilance System
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(6): 501-503.
|
[8] |
CAI Meng, LI Min, SHEN Aizong.
Active Monitoring of Adverse Drug Reactions Caused by Anti-tumor Targeted Drugs
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(4): 368-372.
|
[9] |
WU Fei, LI Min, FANG Yuting, CHEN Yongwu, SHEN Aizong.
Active Monitoring of Adverse Drug Reactions Caused by Lopinavir/ritonavir in Treating Coronavirus Disease 2019
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(2): 105-109.
|
[10] |
WANG Dan, REN Jingtian, DONG Duo, PENG Lili, LIU Wei.
Trend Analysis of Ten-year Annual Reports on Adverse Drug Reaction Monitoring
[J]. Chinese Journal of Pharmacovigilance, 2020, 17(5): 276-283.
|
[11] |
YUAN Lin, GAOYan, LU Changfei.
Preliminary Thinking on the Establishment of Pharmacovigilance System in China
[J]. Chinese Journal of Pharmacovigilance, 2020, 17(11): 749-752.
|
[12] |
ZHOU Hong, XU Ning, ZHANG Xiao, CHEN Gang, LIU Yanjie, YU Xiaojia, GONG Lili, LIU Lihong.
Data Analysis of Oseltamivir Adverse Reactions in 55 Cases
[J]. Chinese Journal of Pharmacovigilance, 2019, 16(7): 420-424.
|
[13] |
DONG Duo ,WU Gui-zhi, WANG Tao, LIU Jia,XIONG Wei-yi,WANG Dan .
The Enlightens on Carrying out Reporting Responsibility of Manufactures in China from Reviewing the Post Marketing Surveillance System in US
[J]. Chinese Journal of Pharmacovigilance, 2017, 14(10): 607-610.
|
[14] |
ZHAO Shi-dan, GAO Xu-guang, DAI Yun-peng, CAO Fei, LIU Li-min, LI Bai-qiang, LU Zhong-ping .
Preliminary Exploration for Construction of Adverse Drug Reaction/Event Sentinel Surveillance in Heilongjiang Province
[J]. Chinese Journal of Pharmacovigilance, 2016, 13(5): 269-271.
|
[15] |
YU Chao, XU Yu-ming, LI Xin-ling, WANG Ling, ZHOU Juan, WAN Kai-hua, XU Jin, YUAN Xin-dong .
Demand Investigation of Interconnection between Hospital Information System and National Adverse Drug Reaction Monitoring System in China
[J]. Chinese Journal of Pharmacovigilance, 2016, 13(3): 154-158.
|